Jane Street Group, LLC Insmed Inc Call Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $16.3 Million - $20.8 Million	263,300 New	263,300 $19.2 Million
Q1 2022 May 17, 2022	SELL	$20.42 - $28.13 $349,182 - $481,023	-17,100 Reduced 40.62%	25,000 $588,000
Q4 2021 Feb 15, 2022	BUY	$25.89 - $33.45 $613,593 - $792,765	23,700 Added 128.8%	42,100 $1.15 Million
Q2 2021 Aug 16, 2021	SELL	$24.17 - $36.01 $183,692 - $273,676	-7,600 Reduced 29.23%	18,400 $524,000
Q1 2021 May 18, 2021	BUY	$32.28 - $44.3 $187,224 - $256,939	5,800 Added 28.71%	26,000 $886,000
Q4 2020 Feb 17, 2021	SELL	$31.45 - $40.54 $2.9 Million - $3.74 Million	-92,200 Reduced 82.03%	20,200 $672,000
Q3 2020 Nov 17, 2020	BUY	$26.0 - $34.5 $1.8 Million - $2.38 Million	69,100 Added 159.58%	112,400 $3.61 Million
Q2 2020 Aug 17, 2020	BUY	$14.11 - $29.42 $245,514 - $511,908	17,400 Added 67.18%	43,300 $1.19 Million
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $300,699 - $808,339	25,900	25,900 $808,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.1B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.